Marinus Pharma (MRNS): רווח למניה בשנים עשר החודשים האחרונים

Marinus Pharmaceuticals revenues rely on insurance coverage approvals and production stability. Net income per share over the last four quarters illustrates profit dynamics, where -2.49 captures the current value of the indicator. The expansion of Ztalmy and the success of new clinical phases will drive growth. The high cost of therapy is supported by orphan drug patents, although revenue is limited by the speed of reimbursement approvals.
פילוחים אנליטיים של חברת Marinus Pharma (MRNS)

Marinus Pharmaceuticals (MRNS) is currently fighting for survival due to failures in the development of a key drug. Net income per share over 12 months is calculated by dividing total annual income by the total number of securities. Analyzing the trend of annual net income per share allows for an assessment of the business's real efficiency. A decline in this metric confirms a loss of competitiveness against industry leaders. Current price action indicates high volatility in market value.